|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer显示文摘Given that only a subset of patients with colorectal cancer(CRC)benefit from immune checkpoint therapy,efforts are ongoing to identify markers that predict immunotherapeutic response.Increasing evidence suggests that microbes influence the efficacy of cancer therapies.Fusobacterium nucleatum induces different immune responses in CRC with different microsatellite-instability(MSI)statuses.Here,we investigated the effect of F.nucleatum on anti-PD-L1 therapy in CRC.We found that high F.nucleatum levels correlate with improved therapeutic responses to PD-1 blockade in patients with CRC.Additionally,F.nucleatum enhanced the antitumor effects of PD-L1 blockade on CRC in mice and prolonged survival.Combining F.nucleatum supplementation with immunotherapy rescued the therapeutic effects of PD-L1 blockade.Furthermore,F.nucleatum induced PD-L1 expression by activating STING signaling and increased the accumulation of interferon-gamma(IFN-γ)^(+)CD8^(+)tumor-infiltrating lymphocytes(TILs)during treatment with PD-L1 blockade,thereby augmenting tumor sensitivity to PD-L1 blockade.Finally,patient-derived organoid models demonstrated that increased F.nucleatum levels correlated with an improved therapeutic response to PD-L1 blockade.These findings suggest that F.nucleatum may modulate immune checkpoint therapy for CRC. | Yaohui Gao Dexi Bi Ruting Xie Man Li Jing Guo Hu Liu Xianling Guo Juemin Fang Tingting Ding Huiyuan Zhu Yuan Cao Meichun Xing Jiayi Zheng Qing Xu Qian Xu Qing Wei Huanlong Qin | 2021 | Signal Transduction and Targeted Therapy2021，6，12： | 3 |
| 2 | Ketogenic diet for human diseases:the underlying mechanisms and potential for clinical implementations显示文摘The ketogenic diet(KD)is a high-fat,adequate-protein,and very-low-carbohydrate diet regimen that mimics the metabolism of the fasting state to induce the production of ketone bodies.The KD has long been established as a remarkably successful dietary approach for the treatment of intractable epilepsy and has increasingly garnered research attention rapidly in the past decade,subject to emerging evidence of the promising therapeutic potential of the KD for various diseases,besides epilepsy,from obesity to malignancies.In this review,we summarize the experimental and/or clinical evidence of the efficacy and safety of the KD in different diseases,and discuss the possible mechanisms of action based on recent advances in understanding the influence of the KD at the cellular and molecular levels.We emphasize that the KD may function through multiple mechanisms,which remain to be further elucidated.The challenges and future directions for the clinical implementation of the KD in the treatment of a spectrum of diseases have been discussed.We suggest that,with encouraging evidence of therapeutic effects and increasing insights into the mechanisms of action,randomized controlled trials should be conducted to elucidate a foundation for the clinical use of the KD. | Huiyuan Zhu Dexi Bi Youhua Zhang Cheng Kong Jiahao Du Xiawei Wu Qing Wei Huanlong Qin | 2022 | Signal Transduction and Targeted Therapy2022，7，2： | 2 |
| 3 | SecReT4:a web-based bacterial typeⅣ secretion system resource显示文摘 | BI Dexi LIU Linmeng TAI Cui | 2013 | Nucleic Acids Research2013，41，： | 1 |
| 4 | Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer显示文摘Correction to:Signal Transduction and Targeted Therapy http://gffzzd3cc09b8251d45dfsbqvbquxukxw56npb.ffgz.tsg.suse.edu.cn/10.1038/S41392-021-00795-x,published online 19 November 2021 In this article^(1) Qing Wei should have been denoted as a corresponding author along with Huanlong Qin,but was inadvertently removed during the production process.The original article has been corrected. | Yaohui Gao Dexi Bi Ruting Xie Man Li Jing Guo Hu Liu Xianling Guo Juemin Fang Tingting Ding Huiyuan Zhu Yuan Cao Meichun Xing Jiayi Zheng Qing Xu Qian Xu Qing Wei Huanlong Qin | 2022 | Signal Transduction and Targeted Therapy2022，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员